Chiruvella Amareshwar, Kooby David A
Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, 1365 C Clifton Road, Northeast, 2nd Floor, Atlanta, GA 30322, USA.
Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, 1365 C Clifton Road, Northeast, 2nd Floor, Atlanta, GA 30322, USA.
Surg Oncol Clin N Am. 2016 Apr;25(2):401-21. doi: 10.1016/j.soc.2015.12.002.
Pancreatic neuroendocrine tumors (pancNETs) are rare neoplasms that comprise 2% to 4% of all clinically detected pancreatic tumors. They are usually indolent, and their malignant potential is often underestimated. The management of this disease poses a challenge because of the heterogeneous clinical presentation and varying degree of aggressiveness. Treatment decisions for this clinical entity are still patient- and/or physician-specific. Optimal clinical management of pancNETs requires a multidisciplinary approach. The only potentially curative treatment option, especially in the early stage disease, remains surgical resection; however, as many as 75% of patients present with advanced disease (nodal and/or distant metastases).
胰腺神经内分泌肿瘤（pancNETs）是罕见肿瘤，占所有临床检测到的胰腺肿瘤的2%至4%。它们通常生长缓慢，其恶性潜能常常被低估。由于临床表现异质性和侵袭程度不同，这种疾病的管理颇具挑战。针对这一临床实体的治疗决策仍因患者和/或医生而异。胰腺神经内分泌肿瘤的最佳临床管理需要多学科方法。唯一可能治愈的治疗选择，尤其是在疾病早期，仍然是手术切除；然而，多达75%的患者就诊时已处于晚期疾病（淋巴结和/或远处转移）。
